{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:49:23Z","timestamp":1774291763147,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1548,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1365-2516.2011.02536.x","type":"journal-article","created":{"date-parts":[[2011,6,6]],"date-time":"2011-06-06T12:09:10Z","timestamp":1307362150000},"page":"962-970","source":"Crossref","is-referenced-by-count":14,"title":["Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog"],"prefix":"10.1111","volume":"17","author":[{"given":"T.","family":"KNUDSEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. T.","family":"KRISTENSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. C.","family":"NICHOLS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"AGERS\u00d8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. L.","family":"JENSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"KJALKE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"EZBAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"TRANHOLM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,6,6]]},"reference":[{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","article-title":"Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors","volume":"2","author":"Abshire","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0038-1642646","article-title":"The tissue factor pathway: how it has become a \u2018prima ballerina\u2019","volume":"74","author":"Rapaport","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.ATV.0000193624.28251.83","article-title":"What does it take to make the perfect clot?","volume":"26","author":"Monroe","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1538-7836.2007.02389.x","article-title":"Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist","volume":"5","author":"Kjalke","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1172\/JCI110939","article-title":"Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors","volume":"71","author":"Hedner","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1073\/pnas.86.4.1382","article-title":"Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease","volume":"86","author":"Brinkhous","year":"1989","journal-title":"Prroc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB8|cit8","first-page":"766","article-title":"Effects of recombinant human activated factor VII and canine fresh frozen plasma in Beagles with hereditary coagulation factor VII deficiency (abstract)","volume":"20","author":"Withnall","year":"2006","journal-title":"J Vet Int Med"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood-2008-07-168377","article-title":"Successful treatment of canine hemophilia by continuous expression of canine FVIIa","volume":"113","author":"Margaritis","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ilar.50.2.144","article-title":"Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency","volume":"50","author":"Nichols","year":"2009","journal-title":"ILAR J"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/j.1538-7836.2010.03931.x","article-title":"Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility","volume":"8","author":"Knudsen","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB12|cit12","article-title":"Detection of canine coated platelets and their rhFVIIa binding by flow cytometry","author":"Knudsen","journal-title":"Am J Vet Res"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/j.1538-7836.2007.02663.x","article-title":"Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors","volume":"5","author":"Konkle","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1111\/j.1365-2516.2011.02536.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1538-7836.2009.03696.x","article-title":"Bio-distribution of pharmacologically administered rFVIIa","volume":"8","author":"Gopalakrishnan","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB15|cit15","first-page":"R126","article-title":"Plasma profiles of IL-6 and TNF with fever-inducing doses of lipopolysaccharide in dogs","volume":"259","author":"LeMay","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1084\/jem.90.2.97","article-title":"Canine Hemophilia: observations on the course, the clotting anomaly, and the effect of blood transfusions","volume":"90","author":"Graham","year":"1949","journal-title":"J Exp Med"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood.V81.3.734.734","article-title":"Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation","volume":"81","author":"Morrissey","year":"1993","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1538-7836.2006.02203.x","article-title":"A novel missense mutation responsible for factor VII deficiency in research Beagle colonies","volume":"4","author":"Callan","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB19|cit19","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2010.11.010","article-title":"Canine specific ELISA for coagulation factor VII","author":"Knudsen","year":"2011","journal-title":"Vet J"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.tvjl.2007.08.022","article-title":"Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs","volume":"179","author":"Wiinberg","year":"2009","journal-title":"Vet J"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00001721-199507000-00012","article-title":"Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species","volume":"6","author":"Ravanat","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/bja\/69.3.307","article-title":"Thrombelastography","volume":"69","author":"Mallett","year":"1992","journal-title":"Br J Anaesth"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/104063870902100508","article-title":"Establishment of reference intervals for kaolin-activated thromboelastography in dogs including an assessment of the effects of sex and anticoagulant use","volume":"21","author":"Bauer","year":"2009","journal-title":"J Vet Diagn Invest"},{"issue":"Suppl.1","key":"10.1111\/j.1365-2516.2011.02536.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1053\/j.seminhematol.2003.11.019","article-title":"Safety profile of recombinant factor VIIa","volume":"41","author":"Roberts","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.CCM.0000159087.85970.38","article-title":"Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review","volume":"33","author":"Levi","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/clpt.1994.80","article-title":"Pharmacokinetics and pharmacodynamics of recombinant factor VIIa","volume":"55","author":"Lindley","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.mbc.0000169218.15926.34","article-title":"A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects","volume":"16","author":"Fridberg","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0021-9258(18)53998-3","article-title":"Complex-dependent inhibition of factor VIIa by antithrombin III and heparin","volume":"268","author":"Lawson","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood.V85.1.121.bloodjournal851121","article-title":"Mechanism of antithrombin III inhibition of factor VIIa\/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor\/factor Xa-induced inhibition of factor VIIa\/tissue factor activity","volume":"85","author":"Rao","year":"1995","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2337\/diabetes.54.6.1755","article-title":"Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation","volume":"54","author":"Johansson","year":"2005","journal-title":"Diabetes"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1160\/TH08-10-0699","article-title":"Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors","volume":"101","author":"Petersen","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.2010.08432.x","article-title":"Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin","volume":"152","author":"Petersen","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1152\/ajplegacy.1967.213.1.36","article-title":"Factor VII survival and turnover in dogs","volume":"213","author":"Dodds","year":"1967","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB34|cit34","first-page":"640","article-title":"Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency","volume":"86","author":"Berrettini","year":"2001","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2004.00925.x","article-title":"Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A","volume":"10","author":"Villar","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1055\/s-2000-8457","article-title":"Pharmacokinetics of recombinant activated factor VII (rFVIIa)","volume":"26","author":"Erhardtsen","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/MBC.0b013e3283001cdc","article-title":"Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial","volume":"19","author":"Young","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1365-2516.2009.02165.x","article-title":"Comparison of kaolin and tissue factor activated thromboelastography in haemophilia","volume":"16","author":"Young","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(03)12268-4","article-title":"Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial","volume":"361","author":"Friederich","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI20106","article-title":"Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII","volume":"113","author":"Margaritis","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1172\/JCI32878","article-title":"Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality","volume":"118","author":"Aljamali","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00001721-199308000-00001","article-title":"Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study","volume":"4","author":"Macik","year":"1993","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1365-2516.2011.02536.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1182\/blood-2009-05-220327","article-title":"Recombinant canine B-domain deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model","volume":"114","author":"Sabatino","year":"2009","journal-title":"Blood"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2011.02536.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2516.2011.02536.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T10:07:00Z","timestamp":1712484420000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2011.02536.x"}},"subtitle":["RECOMBINANT CANINE FVIIA PK\/PD"],"short-title":[],"issued":{"date-parts":[[2011,6,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02536.x","relation":{},"ISSN":["1351-8216"],"issn-type":[{"value":"1351-8216","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6,6]]}}}